Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasm Metastasis × pertuzumab × Clear all

Phase

Phase 2 3 Phase 1/2 2 Phase NA 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 32 HER2-positive Breast Cancer 3 Inflammatory Breast Neoplasms 2 Colonic Neoplasms 2 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Patient Preference 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Invasive Breast Cancer 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2+ Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1 Early or Locally Advanced HER2-positive Breast Cancer 1 Carcinoma, Ductal, Breast 1 Anatomic Stage I Breast Cancer AJCC v8 1 Advanced HER2+Breast Cancer 1 Adenocarcinoma Of Esophagus 1

Interventions

Leucovorin 20 Fluorouracil 20 Capecitabine 19 Docetaxel 18 Gemcitabine 17 Paclitaxel 16 Radiosurgery 13 Irinotecan 13 Carboplatin 12 Zoledronic Acid 11 Oxaliplatin 11 Cisplatin 11 Radiotherapy 10 Fulvestrant 10 Bevacizumab 10 Drug Therapy 9 pembrolizumab 8 Pemetrexed 8 palbociclib 7 Surgical Procedures, Operative 7 Ibandronic Acid 7 Prednisone 6 130-nm albumin-bound paclitaxel 6 abemaciclib 5 Vinorelbine 5 Letrozole 5 Folfox protocol 5 Floxuridine 5 Doxorubicin 5 Cetuximab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡